Navigation Links
Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
Date:2/26/2008

sed patients, such as those with HIV-AIDS or undergoing bone marrow transplantation. Given this lead, Lixte is initiating studies to assess the potential value of these compounds for treatment of serious fungal diseases."

About Lixte Biotechnology Holdings, Inc.:

Lixte Biotechnology Holdings, Inc. (Lixte) is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, Lixte develops new chemotherapy drugs targeting molecular abnormalities of common human cancers. Over the past year, based on the discovery of a new biomarker for brain cancers by collaborators at NIH, the company is working with NINDS, NIH to develop more effective treatments for glioblastoma multiforme (GBM), the most common and most aggressive type of primary brain cancer in adults and other brain cancers of adults and children.

GBM occurs annually in 20,000 to 25,000 adults in the United States and in a comparable number of individuals in Europe. At present, there is no curative treatment known for this disease. Standard treatment involves surgery, radiation and the use of one or more chemotherapeutic agents at the time of initial treatment. At relapse, which occurs in essentially all patients, the present standard treatment is a drug, Temozolomide, which is associated with a modest increase in life span measured in weeks. Thus, there is an urgent need for more effective treatments for GBM.

About the National Institute of Neurological Disorders and Stroke (NINDS), (NIH):

NINDS (http://www.ninds.nih.gov) is a component of the National Institutes of Health (NIH), and is the nation's primary supporter of biomedical research on the brain and nervous system.

The National Institutes of Health (NIH) -- The Nation's Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal ag
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Opportunities to Invest in Puerto Rico as Global Center for Biotechnology
2. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
3. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
4. 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
5. Cardinal Health CEO of Clinical & Medical Products to Speak at Merrill Lynchs Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
9. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
10. BD to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
11. Biotechnology Builds a New Heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... 28, 2015 , ... According to WFTV on July 15th heroin ... heroin toxicity cases. According to recent statistic Orlando suffers at least one death weekly ... hub of heroin, and law enforcement officials are struggling to keep apace with its ...
(Date:7/28/2015)... ... July 28, 2015 , ... Brookstone®, a ... System to its online product offerings, giving its customers the opportunity to ... cloud-based technology, SmileCareClub allows patients to get quality, remote invisible aligner treatment from ...
(Date:7/28/2015)... ... July 28, 2015 , ... A new Taiwanese study suggests ... are in the general population. Surviving Mesothelioma has just posted an article detailing ... at Taiwan’s National Health Research Institutes and three Taiwanese universities evaluated the health ...
(Date:7/28/2015)... ... ... Fertility specialist Dr. Lisa Hasty of Atlanta Center for Reproductive ... Atlanta Magazine's annual Top Doctors issue, Dr. Hasty has been recognized for the fifth ... metro area as one of the most respected doctors in Reproductive Endocrinology. , “I’m ...
(Date:7/28/2015)... ... July 28, 2015 , ... A June ... Wright's Spinal Stenosis Injury" discussed baseball player David Wright’s spinal stenosis injury and ... stenosis, brought on by degenerative changes in the spine, rather than congenital, which ...
Breaking Medicine News(10 mins):Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 2Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 3Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 2Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 3Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 2Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 3
... in the UK most people believe that asthma is a ... asthma develop the condition in adulthood and it can be ... early stages. Asthma can occur in an individual for the ... where many people don't realise they have asthma.// However, around ...
... The Diabetes Research and Wellness Foundation is predicting a 300pc ... Diabetes, though other experts say this figure is possibly a ... is indicated that an epidemic of type two diabetes is ... lead to heart disease, blindness and kidney failure. It is ...
... cells has cured mice suffering with a form of ... of their back legs, and many showed improvement. Researchers ... the brains of adult in the bloodstream or spinal ... had migrated to and then repaired damaged areas of ...
... World Health Organization said that it should take three to ... China. Since mid-February, an international team from WHO has been ... full partner with China in the investigation of SARS. China ... accounting for about half of the global total. The WHO ...
... its a common belief that asthma is a condition ... most common long-term conditions affecting people in the UK. ... that around 40% of people with asthma develop the ... are not recognised and corrected. However, around two-thirds// of ...
... expecting moms will do whatever needs to be done. ,Whether it ... moms who smoke, ready to set ,aside their habit or smokers ... habit on ,hold for the sake of the child? ,A ... County Tobacco Control Committee was ,that// Baxter County has the highest ...
Cached Medicine News:
(Date:7/28/2015)...  CryoLife, Inc. (NYSE: CRY ), a leading ... and vascular surgery, announced today its results for the ... Pat Mackin, Chairman, President and Chief Executive ... on our growth strategy with solid progress on several ... plans to transition to a direct sales model in ...
(Date:7/28/2015)... -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP ) announced ... quarter and year-to-date 2015 financial results on Tuesday, August ... markets. The earnings press release will be accessible through ... www.anipharmaceuticals.com . Arthur S. Przybyl , ... Arnold , Vice President and Chief Financial Officer, also ...
(Date:7/28/2015)... HACKENSACK, N.J., July 28, 2015  Champions Oncology, Inc. ... solutions and services to personalize the development and use ... the year ended April 30, 2015. Fourth ... increased 32% over the same prior year period result ... than 140 implants Joel Ackerman, Champions Oncology ...
Breaking Medicine Technology:CryoLife Reports Second Quarter Financial Results 2CryoLife Reports Second Quarter Financial Results 3CryoLife Reports Second Quarter Financial Results 4CryoLife Reports Second Quarter Financial Results 5CryoLife Reports Second Quarter Financial Results 6CryoLife Reports Second Quarter Financial Results 7CryoLife Reports Second Quarter Financial Results 8CryoLife Reports Second Quarter Financial Results 9CryoLife Reports Second Quarter Financial Results 10CryoLife Reports Second Quarter Financial Results 11CryoLife Reports Second Quarter Financial Results 12CryoLife Reports Second Quarter Financial Results 13CryoLife Reports Second Quarter Financial Results 14ANI Pharmaceuticals Schedules Conference Call for Second Quarter and Year-to-Date 2015 Financial Results 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 3Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 4Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 5Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 6Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 7Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 8Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 9Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 10Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 11
... 19, 2007 - Amgen,(NASDAQ: AMGN) today ... study", a,randomized, double-blind, placebo-controlled, multicenter Phase ... 600 previously untreated,patients with extensive-stage small-cell ... study demonstrated,no statistically significant difference in ...
... Biomolecular Sciences Conference, THE WOODLANDS, Texas, April ... that data was presented,today highlighting potential therapeutic ... at the Society for Biomolecular,Sciences 13th Annual ... discoveries were made in a collaboration,between Lexicon ...
Cached Medicine Technology:Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 2Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 3Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 4Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 5Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 6Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 7Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 2Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 3Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 4Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 5
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: